In this narrative review, we focus on current strategies targeting PCSK9 and critically discuss some uncertainties regarding the allocation strategy, paying particular attention on the role of inclisiran in the treatment of dyslipidemia in high-/very high-risk subjects. This evidence concerns the gene PCSK9 and metabolic syndrome.